Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

CDS022971

Sigma-Aldrich

Lapatinib

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

25 MG
€ 111,00

€ 111,00

Versand innerhalb von 2 Werktagen (Bei Bestellungen außerhalb der USA rechnen Sie bitte zusätzlich 1-2 Wochen für die Lieferung ein)
Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
25 MG
€ 111,00

About This Item

Empirische Formel (Hill-System):
C29H26ClFN4O4S
CAS-Nummer:
231277-92-2
Molekulargewicht:
581.06
MDL-Nummer:
MFCD09264194
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329796232

€ 111,00

Versand innerhalb von 2 Werktagen (Bei Bestellungen außerhalb der USA rechnen Sie bitte zusätzlich 1-2 Wochen für die Lieferung ein)
Bulk-Bestellung anfordern

Beschreibung

AldrichCPR

Form

solid

SMILES String

CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O

InChI

1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

InChIKey

BCFGMOOMADDAQU-UHFFFAOYSA-N

Angaben zum Gen

human ... EGFR(1956) , ERBB2(2064)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Lapatinib is a tyrosine kinase inhibitor, targeting both the epidermal growth factor receptors, ErbB1 and ErbB-2. In combination with trastuzumab, it is reported to show complementary mechanisms of action and synergistic antitumor activity in breast cancer.[1][2]

Sonstige Hinweise

Please note that Sigma-Aldrich provides this product to early discovery researchers as part of a collection of unique chemicals. Sigma-Aldrich does not collect analytical data for this product. Buyer assumes responsibility to confirm product identity and/or purity. All sales are final.

NOTWITHSTANDING ANY CONTRARY PROVISION CONTAINED IN SIGMA-ALDRICH′S STANDARD TERMS AND CONDITIONS OF SALE OR AN AGREEMENT BETWEEN SIGMA-ALDRICH AND BUYER, SIGMA-ALDRICH SELLS THIS PRODUCT "AS-IS" AND MAKES NO REPRESENTATION OR WARRANTY WHATSOEVER WITH RESPECT TO THIS PRODUCT, INCLUDING ANY (A) WARRANTY OF MERCHANTABILITY, (B) WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, OR (C) WARRANTY AGAINST INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF A THIRD PARTY, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE.

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

Gefahreneinstufungen

Aquatic Chronic 4 - Eye Irrit. 2 - Lact.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 7

1 of 7

Dasatinib

Sigma-Aldrich

CDS023389

Dasatinib

Sorafenib European Pharmacopoeia (EP) Reference Standard

Y0002098

Sorafenib

PHTPP ≥98% (HPLC)

Sigma-Aldrich

SML1355

PHTPP

Crizotinib ≥98% (HPLC)

Sigma-Aldrich

PZ0191

Crizotinib

Capecitabin ≥98% (HPLC)

Sigma-Aldrich

SML0653

Capecitabin

Saquinavir -mesylat ≥98% (HPLC), powder

Sigma-Aldrich

S8451

Saquinavir -mesylat

Imatinib

Sigma-Aldrich

CDS022173

Imatinib

Aleksandra Simiczyjew et al.
Cancers, 10(9) (2018-09-20)
Triple-negative breast cancer (TNBC) is the most challenging subtype to treat due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, which excludes the usage of directed targeted therapy against them. Promising therapeutic targets are the hepatocyte growth
Shota Tanaka et al.
Scientific reports, 9(1), 139-139 (2019-01-16)
Intratumoural heterogeneity underlies tumour escape from molecularly targeted therapy in glioblastoma. A cell-based model preserving the evolving molecular profiles of a tumour during treatment is key to understanding the recurrence mechanisms and development of strategies to overcome resistance. In this
Tushar Piyush et al.
Cell death and differentiation, 24(11), 1937-1947 (2017-07-22)
Epidermal growth factor receptor (EGFR) is an important regulator of epithelial cell growth and survival in normal and cancerous tissues and is a principal therapeutic target for cancer treatment. EGFR is associated in epithelial cells with the heavily glycosylated transmembrane
Melinda Halasz et al.
Science signaling, 9(455), ra114-ra114 (2016-11-24)
Signal transduction networks are often rewired in cancer cells. Identifying these alterations will enable more effective cancer treatment. We developed a computational framework that can identify, reconstruct, and mechanistically model these rewired networks from noisy and incomplete perturbation response data
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga J, et al.
The Lancet, 379(9816), 633-640 (2012)
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.